Our main research aim is to characterize and better understand the major signaling pathways involved in diabetes development by studying developing pancreatic cells differentiated from induced pluripotent stem cells (iPSCs) generated from families with monogenic diabetes.
The group’s main recent research achievement has been the successful making of human iPSCs from fibroblasts from several members in families with MODY1 and characterise the proteome of the differentiated cells (Vethe et al., 2017 Sci Rep). Moreover, we have been using proteomics to define the pancreatic secretome in MODY8 patients (Bjørlykke et al, J Proteom Res. 2015; Ræder et al., Diabetes, 2014).
The lab is funded by Bergen Research Foundation, University of Bergen, Western Norway Regional Health Authority, Novo Nordisk Foundation and is based in the KG Jebsen center for Diabetes Research, Department of Clinical Science, University of Bergen, Norway.